Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Share
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Mohamed El-Erian, Allianz chief economic advisor and president of Queens’ College, Cambridge, joins ‘Squawk Box’ to discuss the latest market trends, what to expect from today’s December CPI data, the impact on the Fed’s rate path decision, and more.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Matt Bryson of Wedbush Securities joins ‘TechCheck’ to discuss the swelling supply of semiconductors, bullish picks for the chip sector and the outlook for chip providers in gaming. 04:32 Tue, Dec 27 202212:08 PM EST
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Harsh Kumar, Piper Sandler analyst, joins ‘Squawk on the Street’ to discuss his thoughts on Nvidia’s earnings and why he believes the company gave ‘perfect guide’ for the quarter. 02:54 Thu, Feb 23 202311:12 AM EST
Gerard Lyons tells CNBC there is too much fear about leaving the EU without a deal.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email “Fast Money Halftime Report” is on the front lines of CNBC’s market coverage. Host CNBC’s Scott Wapner and the Street’s top investors get to the heart of the action as it’s happening and help set the agenda for the rest of the…
Suze Orman remembers some the most memorable moments from her “Can I Afford It” segment.